Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

NCT02777073 · Completed

Last updated 2026-05-28

This clinical trial tested how single doses of liraglutide and dapagliflozin affect ketone levels in people with type 1 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 43 people

Who can join Ages 18–75 · all sexes

Timeline Started 2016-03 · est. completion 2016-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02777073 ↗

Description as written by the study sponsor.

1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Ll-6 and IL-1 before and after administration of liraglutide/placebo.

Treatments tested

Victoza also known as Liraglutide Drug

Single dose of Liraglutide
Placebo Drug

Single dose of generic placebo
Dapagliflozin 10mg Tab also known as Dapagliflozin Drug

single dose of 10 mg dapagliflozin

Main thing measured	Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin
Sponsor	University at Buffalo
Conditions studied	Type 1 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02777073 ↗